The FDA approved Jideytro (zidesamtinib) for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer previously treated with a ROS1 inhibitor. In 117 patients from ARROS-1, the objective response rate was 44%,…
GSK agreed to acquire Nuvalent for approximately $10.6 billion, one of the largest biotech acquisitions of 2026. The transaction adds late-stage ROS1 and ALK targeted oncology assets and significantly accelerates GSK’s effort to rebuild…
GSK has signed an oligonucleotide licensing agreement with China-based SiranBio worth up to $1 billion to develop SA030, a Phase 1-stage ALK7-targeting therapy for metabolic disease and abdominal fat reduction.
